Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 4/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31534710 | 1.00 | DDR1 (0.35) | DDR1IRAK4MAPTRORCKDM4E | |
| SCHEMBL31534712 | 0.90 | DHODH (0.35) | DDR1MAPTRORCCNR2HPGD | |
| SCHEMBL17967743 | 0.90 | DHODH (0.35) | DDR1MAPTRORCCNR2HPGD | |
| SCHEMBL31534708 | 0.89 | DDR1 (0.39) | DDR1IRAK4RORCSCN9A | |
| SCHEMBL18013098 | 0.89 | DDR1 (0.39) | DDR1IRAK4RORCSCN9A | |
| SCHEMBL19767669 | 0.88 | KDM4E (0.34) | MAPTRORCKDM4EALOX5AP | |
| SCHEMBL31534706 | 0.86 | RORC (0.33) | DDR1RORCCNR2LRRK2 | |
| SCHEMBL18013099 | 0.86 | RORC (0.33) | DDR1RORCCNR2LRRK2 | |
| SCHEMBL19876693 | 0.85 | MAPT (0.37) | MAPTKDM4EALDH1A1HPGDSCN9A | |
| SCHEMBL18506249 | 0.84 | DDR1 (0.35) | DDR1MAPTRORCKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253757-B1 | 2-(HET)ARYL-SUBSTITUTED CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2025-03-19 | — | — | EP | disclosed |
| CN-107428759-B | 2- (hetero) aryl-substituted fused bicyclic heterocyclic derivatives as pest control agents | 拜耳作物科学股份公司 | 2020-11-27 | — | — | CN | disclosed |
| US-10654845-B2 | 2-(het)aryl-substituted fused bicyclic heterocycle derivatives as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| US-20180016273-A1 | 2-(HET)ARYL-SUBSTITUTED FUSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
| WO-2016124557-A1 | 2-(HET)ARYL-SUBSTITUTED CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016124557-A1 | 2-(HET)ARYL-SUBSTITUTED CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016273-A1 | 2-(HET)ARYL-SUBSTITUTED FUSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | CYP4B1, CYP1B1, CYP8B1 | DDR1 3091/4885IRAK4 2480/4885MAPT 4794/4885 |
| US-10654845-B2 | 2-(het)aryl-substituted fused bicyclic heterocycle derivatives as pesticides | CYP4B1, CYP1B1, CYP8B1 | DDR1 3241/4885IRAK4 2496/4885MAPT 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.